We have identified and characterized two mutations in the hormone binding domain of the vitamin D receptor (VDR) in patients with hereditary vitamin D-resistant rickets. One patient was found to have a premature stop mutation (CAG to TAG) in the hinge region affecting amino acid 149 (Q149X) and the other demonstrated a missense mutation (CGC to CTC) resulting in the substitution of arginine 271 by leucine (R271L) in the steroid binding domain. Eukaryotic expression analyses in CV-1 cells showed the inability of both patients' VDR to induce transcription from the osteocalcin hormone gene response element at 10-7 M 1,25-dihydroxyvitamin D3 (1,25(OH)2D3). Normal transcription levels could, however, be elicted by the missense mutated VDR (R271L) in the presence of 1,000-fold higher 1,25-(OH)2D3 concentrations than needed for the wildtype receptor. This shows that Arg 271 directly affects the affinity of the VDR for its ligand and its conversion to leucine decreases its affinity for 1,25(OH)2D3 by a factor of 1,000. Arg 271 is located immediately 3-prime to a 30 amino acid segment (VDR amino acids 241-270) that is conserved among members of the steroid/thyroid /retinoid hormone receptor superfamily. These results represent the first missense mutation identified in the hormone binding domain of VDR and further define the structure-function relationship of 1,25(OH)2D3 ligand binding to its nuclear receptor. (J. Clin. Invest. 1993. 92:12-16.)
Introduction
The biological effects of 1,25-dihydroxyvitamin D3 (1, 25 (OH )2D3),l the hormonal form of vitamin D, are mediated by its binding to a specific intracellular receptor present in target cells (1) (2) (3) . The 48-kD receptor belongs to the family of steroid/thyroid/retinoid nuclear hormone receptors (4). These receptors act in trans by binding to specific cis-acting DNA sequences in the promotor regions of hormone-responsive genes, thereby modulating their transcription (5) . Receptors belonging to this superfamily comprise two functional domains: a ligand binding and a DNA binding domain (4) . The DNA binding domains show high evolutionary conservation in a region of 60-70 residues that form two zinc fingers essential for interaction with DNA (4, (6) (7) (8) (9) (10) . The high amino acid homology within this region predicts a three-dimensional organization common to the individual members of the gene family. The interaction of the glucocorticoid receptor DNA binding domain with its DNA hormone response element has recently been resolved by crystallographic analysis (11) , and on this basis we have analyzed the stereochemical consequences of vitamin D receptor (VDR) mutations identified in patients with tissue resistance to 1,25(OH)2D3 (12) .
Structure-function relationships of the hormone binding domain are much less well understood. The potential importance of individual amino acids in this domain is inferred by their evolutionary conservation throughout the receptor superfamily (4) . For example, subdomains within the carboxy-terminal halfofthese receptors that affect ligand binding, receptor dimerization, and transcriptional activation have been identified (9, (13) (14) (15) (16) (17) . Further insight has been obtained from mutations intentionally created in this domain, together with reports of receptor mutations in patients with tissue resistance to the various steroid hormones (9, 13, 15, (18) (19) (20) (21) (22) (23) (24) (25) (26) . Only one of the published mutations in the human VDR has been in the hormone binding domain (25) . Here Cloning and sequencing ofamplified DNA. The PCR products were cloned into Bluescript II pSK-plasmid (Stratagene, La Jolla, CA). Positive clones were sequenced by the dideoxy chain termination method using fluorescence labeled M1 3 reverse primer on an automated sequencer (Applied Biosystems, Inc., Foster City, CA). The full-length VDR coding region was subcloned in a sense orientation into the EcoR I and Xba I sites ofthe expression vector pSVK3 (Pharmacia, LKB Biotechnology Inc., Piscataway, NJ) (31) . For exclusion of Taq polymerase and sequencing errors, all steps were performed in duplicate, starting with the reverse transcriptase reaction, and several clones of each PCR product were sequenced in both orientations.
Reporter construct. A 881-bp 5'-untranslated fragment of the human osteocalcin gene including the VDR hormone response element (32) was amplified by PCR from human genomic DNA using the following primers: 5'-CTGCAGGGTCAGGAGGAGAATCG and 5'-GTCGCGTCGGTGGGCTCT. Reaction conditions included standard Cetus buffer, 2.0 mM MgCl2, and 0.2 MM primer concentration for 35 cycles of 95°C for 1 minm 58°C for 1 min, and 72°C for 2 min. The PCR product was cloned into the reporter plasmid pCAT Basic (Promega Corp., Madison, WI), thereby fusing the osteocalcin gene promoter/enhancer region upstream of the chloramphenicol acetyltransferase (CAT) gene.
VDR cotransfection assay in CV-J cells. VDR-deficient CV-l cells were grown in DME supplemented with 10% FCS and L-glutamine (2 mM). 24 h before transfection the cells were plated to a density of 1 X 106 cells/ 10-cm plate. Transfection was carried out by the polybrene method as described (7) Fig. 2 ), replacing the normal glutamine codon with a termination codon and resulting in a truncated receptor missing 303 residues of the hormone binding domain. The other patient demonstrated a substitution of a G for a T in codon 271, resulting in a missense mutation (CGC to CTC), with exchange of a basic hydrophobic arginine for a nonpolar, hydrophobic leucine (Fig. 2) . In both patients and in four others (unpublished results) we identified a single initiation codon (ATG) at nucleotide position 125, counting from the beginning of the published sequence (GenBank# J03258) (7). This is different from the originally reported sequence in which two putative transcription initiation sites (at 116 and 125 bp) were found (7). The former of these was absent in all of our patients, consistent with the findings of Saijo et al. (35) . This could represent a polymorphism in the population resulting in two different receptor species that differ in length by 3 amino acids at the amino terminus. Our numbering of amino acids and their codons is from the single initiation site at position 125. S for the wild-type protein (Fig. 4) . Consequently, mutation R271L decreases the affinity of the VDR for the ligand by 1,000-fold.
Discussion
It is now well established that HVDRR is caused by mutations in the VDR (25, 35, 36) . With increasing knowledge about the structure-function relationship ofthe different members in the steroid/thyroid/retinoid receptor superfamily, it is now possible to be more specific about the effects of various mutations. This is especially true for the DNA binding domain of the receptors but increasing evidence is also accumulating regarding the function of subdomains and individual amino acids in the hormone binding domain (9, 13, 17, 25) . Deletion construct analysis has suggested that the critical point for NH2-terminal deletions still giving high affinity wild-type binding of 1,25(OH)2D3 lies between residues 1 14 and 166 (9) . Our mutation at codon 149 narrows this further by the fact that there is no detectable cytosolic binding of 1,25(OH)2D3 (27, 28) . The COOH-terminal portion of the glucocorticoid receptor (37, 38) , androgen receptor ( 18, 22) , progesterone receptor (39), estrogen receptor (40, 41 ) , and the VDR (9) have been shown to have a repressive effect on transcriptional activation in the absence of ligands. A VDR deletion mutant missing the carboxyl portion from residue 190 to the 3' terminus has been shown to exhibit considerable constitutive transcriptional activity (9) . Similar data exist for the glucocorticoid receptor and the androgen receptor (18, 22, 37, 38) . This has been interpreted as evidence for transcriptional domains being present in the amino-terminal portion of the hormone binding domains.
This region of the VDR is rich in acidic residues (42) that have been implicated as being important in gene activation within yeast transcription factors (43) and steroid receptors (44) . In the mammalian cotransfection analyses reported here, no transcriptional activation by the cDNA Q149X mutant was detected. This could be explained by deletion of these transcriptional activation domains. Additionally, a premature stop mutation at codon 149 not only deletes the entire portion of the molecule that is postulated to form the actual binding pocket for 1,25 (OH)2D3, but it also deletes a dimerization domain that is essential for receptor binding to the VDR hormone response element. This domain (VDR residues 241-263; Fig. 5) is highly conserved between all the members ofthe superfamily and is involved in interaction with nuclear proteins ( 13, 15, 23) , possibly RXRbeta ( 14, 16) . Point mutations within this domain do not interfere with ligand binding but affect the ability of the receptors to form heterodimers, bind with their response elements, and initiate transcription (13, 15, 23 (Fig. 5 ). This residue is conserved among the VDR, thyroid receptor, and retinoic acid receptor, and it is possible that it provides an important ligand contact or represents a polar residue critical for the three-dimensional structure of this domain. Our data do not clarify the role of Arg 271 in this regard, but the importance ofthis residue is emphasized by the recent observation that a mutation at this position (A746D) in the androgen receptor results in androgen insensitivity syndrome (26) . We have described two novel mutations in the hormone binding domain of the VDR that give further insight to the structure-function relationship of this part of the protein.
There is increasing evidence that binding of 1,25(OH)2D3 to the VDR modifies protein-protein interaction and transcriptional activation through modification of the receptor's structure. The full understanding ofthe structure-function relationship of the hormone binding domains of the steroid/thyroid/ retinoid receptors awaits the determination of their three-dimensional structure by x-ray crystallography.
